The DEA just scheduled centanafadine as Schedule III. The internet is about to lose its mind over this one. Jonathan Murphy, PMHNP-BC, breaks it down before the marketing noise drowns out the clinical reality.
Simtriyo is a new ADHD medication approved by the FDA in July 2026, now scheduled by the DEA as of October 30, 2026. It is being marketed as a first-in-class triple reuptake inhibitor hitting norepinephrine, dopamine, and serotonin. The binding data tells a different story. The serotonin piece is likely not clinically relevant at therapeutic doses. The effect size is roughly one-third of traditional stimulants. No head-to-head trial against any existing ADHD medication was ever conducted. Two black box warnings: abuse potential and suicidality.
This episode covers what Schedule III actually means versus Schedule II, how Otsuka Pharmaceutical developed the drug, why the triple reuptake inhibitor label is marketing language, why the serotonin claim is unproven, the abuse potential data from primate self-administration studies, why the suicidality warning matters for patients with mood instability, and why the honest clinical recommendation is to wait a year.
The Process: An Adult’s Guide to ADHD Medication, available on Amazon
Focus Path YouTube Channel: @FocusPathSystems
X (Twitter): @ADHDAuthority